No Fluff. Just Sources.
Pipeline Deep Dive

CagriSema & SURMOUNT-5: The Next-Gen GLP-1 Trial Results Explained

CagriSema hit 22.7% weight loss. Tirzepatide beat semaglutide head-to-head in SURMOUNT-5. High-dose CagriSema trials begin later in 2026. Here's what every trial showed and what it means for patients.

Published May 2026 · Sources verified May 2026

The GLP-1 drug class is evolving fast. Two landmark datasets — the SURMOUNT-5 head-to-head trial and Novo Nordisk's REDEFINE program for CagriSema — have reshaped how clinicians and patients think about which drug to choose and what's coming next. Here's the data, stripped of marketing language.

SURMOUNT-5: Tirzepatide vs Semaglutide, Head-to-Head

-20.2% vs -13.7% In SURMOUNT-5, tirzepatide produced 20.2% mean weight loss at 72 weeks compared to 13.7% for semaglutide — a 6.5-percentage-point advantage. Published in the New England Journal of Medicine, May 2025.

SURMOUNT-5 was the first published head-to-head Phase 3b trial comparing the two leading obesity medications. The trial enrolled 751 adults with obesity (without diabetes) and randomized them 1:1 to tirzepatide or semaglutide for 72 weeks, titrated to maximum tolerated dose.

Outcome Tirzepatide Semaglutide P-value
Mean weight loss -20.2% -13.7% <0.001
Waist circumference change -18.4 cm -13.0 cm <0.001
≥15% weight loss achieved Higher Lower <0.001
GI discontinuation rate 2.7% 5.6% —

Two things worth noting: First, the 6.5-percentage-point gap is clinically meaningful, but both drugs are genuinely effective — semaglutide's 13.7% is itself far above what any previous non-surgical intervention achieved. Second, tirzepatide had a lower GI discontinuation rate (2.7%) than semaglutide (5.6%), meaning it was actually better tolerated despite producing more weight loss. Third, SURMOUNT-5 was funded by Eli Lilly (which manufactures tirzepatide) — standard for Phase 3 trials, but worth noting.

A post-hoc cardiovascular risk analysis estimated that tirzepatide could prevent approximately 2 million cardiovascular events over 10 years in the eligible US population, compared to 1.15 million with semaglutide — a significant difference in projected population-level impact.

CagriSema: The Amylin + GLP-1 Combination

22.7% CagriSema (cagrilintide 2.4mg + semaglutide 2.4mg) produced 22.7% mean weight loss at 68 weeks in REDEFINE 1. FDA application filed December 2025; review expected 2026.

CagriSema is Novo Nordisk's answer to the competitive pressure from tirzepatide. It combines semaglutide (the GLP-1 agonist in Wegovy) with cagrilintide, a long-acting amylin analogue — a different class of appetite-regulating hormone. The idea is that targeting two distinct pathways (GLP-1 + amylin) produces additive weight loss beyond what either drug achieves alone.

REDEFINE 1 enrolled 3,417 adults with obesity in a 68-week trial. CagriSema at the 2.4mg/2.4mg dose produced 22.7% mean weight loss — significantly more than semaglutide 2.4mg alone (15.5%) and cagrilintide alone (8.5%). Novo Nordisk filed for FDA approval in December 2025, and a review decision is expected in 2026.

In REDEFINE 4, an 84-week open-label trial comparing CagriSema directly against tirzepatide 15mg, CagriSema achieved 23.0% weight loss compared to tirzepatide's 25.5%. While tirzepatide won this head-to-head comparison, Novo Nordisk has pointed out that higher-dose CagriSema formulations (2.4mg/7.2mg) are being developed that may close or reverse this gap.

What's Still Coming

Drug Class Key Data Status
CagriSema (high-dose) GLP-1 + Amylin Phase 3 trial H2 2026 Enrolling
Retatrutide Triple agonist (GIP/GLP-1/Glucagon) Phase 2: ~24% at 48 wks Phase 3 ongoing
Survodutide GLP-1 + Glucagon 83% MASH improvement Phase 3 for obesity + liver
Orforglipron Oral GLP-1 (non-peptide) Daily pill Phase 3 ongoing
What This Means for Patients Now

These next-gen drugs are 1–3 years from market availability. In the meantime, semaglutide and tirzepatide remain the best available options — both are highly effective, and the choice between them should be individualized based on response, tolerance, and cost. Compounded versions of current-gen drugs offer the most affordable access point while we wait for the pipeline to mature.

Editor's Pick
💰 Budget Pick
GobyMeds

The lowest entry price we've found for compounded GLP-1 medications. No membership fees, no consultation fees, free refrigerated shipping. LegitScript certified with 503A + 503B pharmacy partners.

Semaglutide
$99/mo
12-week starter bundle
Tirzepatide
$133/mo
12-week starter bundle
✅ Free consultation ✅ Free overnight shipping ✅ No membership required ✅ HSA/FSA accepted ✅ LegitScript certified ✅ Also offers NAD+ & Sermorelin
💰 Use code x7X72r to save $25 on your first order
Get Started With GobyMeds →

Paid link · Compounded medications are not FDA-approved

Sources

  1. Aronne L, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. May 2025.
  2. ACC. "SURMOUNT-5: Greater Loss of Weight, Waist Circumference With Tirzepatide Than Semaglutide." July 2025. acc.org
  3. Novo Nordisk. REDEFINE 1 headline results: CagriSema 22.7% weight loss at 68 weeks. NEJM June 2025.
  4. Novo Nordisk. REDEFINE 4 headline results: CagriSema 23.0% vs tirzepatide 25.5% at 84 weeks. February 2026. novonordisk.com
  5. Novo Nordisk. CagriSema NDA filed with FDA, December 2025. prnewswire.com
  6. Drugs.com. CagriSema pipeline status. Updated February 2026. drugs.com

Affiliate Disclosure: Some provider links on this page are affiliate links. If you sign up through these links, we may receive compensation at no additional cost to you. This does not influence our editorial content, pricing data, or provider selection.